ERNA Eterna Therapeutics, Inc.: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

The blood cancer treatment sector relies on securing venture capital for clinical trials. Eterna Therapeutics (ERNA) utilizes mRNA and CRISPR for precise cell programming, ensuring macro-resilient demand regardless of GDP. The TTM annual net income per share dynamics reflect current trends, where the value of 86.30 characterizes this level of operational momentum.
פילוחי מדדים פיננסיים ומדדי שוק עבור Eterna Therapeutics Inc (ERNA)

The continuity of component supplies for cell engineering at Eterna Therapeutics (ERNA) directly impacts operational efficiency. The twelve-month earnings per share (EPS) trend aggregates these costs, reflecting the actual growth rate of net yield. This metric compares current earnings with the previous period to assess capital efficiency. It is critical for investors to correlate this growth with resource costs. By analyzing the rolling annual EPS change, one can identify the resilience of the business model.